Anjla Sood

683 total citations · 1 hit paper
10 papers, 476 citations indexed

About

Anjla Sood is a scholar working on Molecular Biology, Hematology and Infectious Diseases. According to data from OpenAlex, Anjla Sood has authored 10 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Hematology and 1 paper in Infectious Diseases. Recurrent topics in Anjla Sood's work include Protein Degradation and Inhibitors (9 papers), Multiple Myeloma Research and Treatments (8 papers) and Acute Myeloid Leukemia Research (3 papers). Anjla Sood is often cited by papers focused on Protein Degradation and Inhibitors (9 papers), Multiple Myeloma Research and Treatments (8 papers) and Acute Myeloid Leukemia Research (3 papers). Anjla Sood collaborates with scholars based in United States, Australia and United Kingdom. Anjla Sood's co-authors include Kevin J. Freise, Kenshi Suzuki, Hans Salwender, Paulo Maciag, Jeremy A. Ross, Elizabeth A. Punnoose, Rakesh Popat, Shaji Kumar, Vânia Hungria and Javier de la Rubia and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Anjla Sood

10 papers receiving 467 citations

Hit Papers

Venetoclax or placebo in combination with bortezomib and ... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
    2020 256 citations Shaji Kumar, Simon J. Harrison et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anjla Sood United States 7 385 346 181 63 28 10 476
Connie Qi Canada 8 236 0.6× 269 0.8× 137 0.8× 76 1.2× 56 2.0× 14 350
Ammar Al-Zoubi United States 5 370 1.0× 377 1.1× 200 1.1× 71 1.1× 48 1.7× 11 455
Edmund C. Lee United States 4 394 1.0× 179 0.5× 171 0.9× 36 0.6× 34 1.2× 4 468
Noa Biran United States 12 256 0.7× 322 0.9× 226 1.2× 35 0.6× 24 0.9× 89 427
Edvan de Queiroz Crusoé Brazil 8 233 0.6× 229 0.7× 156 0.9× 33 0.5× 21 0.8× 41 353
Claire Torre United States 7 336 0.9× 346 1.0× 177 1.0× 47 0.7× 34 1.2× 15 505
Joe Bolen United States 1 347 0.9× 178 0.5× 169 0.9× 36 0.6× 26 0.9× 3 409
Ellen Ingalla United States 5 241 0.6× 127 0.4× 126 0.7× 69 1.1× 49 1.8× 12 339
Vladimir Vorobyev Russia 10 185 0.5× 228 0.7× 137 0.8× 85 1.3× 45 1.6× 39 383
Evžen Gregora Czechia 11 218 0.6× 253 0.7× 130 0.7× 43 0.7× 22 0.8× 29 301

Countries citing papers authored by Anjla Sood

Since Specialization
Citations

This map shows the geographic impact of Anjla Sood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anjla Sood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anjla Sood more than expected).

Fields of papers citing papers by Anjla Sood

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anjla Sood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anjla Sood. The network helps show where Anjla Sood may publish in the future.

Co-authorship network of co-authors of Anjla Sood

This figure shows the co-authorship network connecting the top 25 collaborators of Anjla Sood. A scholar is included among the top collaborators of Anjla Sood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anjla Sood. Anjla Sood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Kumar, Shaji, Simon J. Harrison, Michèle Cavo, et al.. (2020). Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology. 21(12). 1630–1642. 256 indexed citations breakdown →
2.
Kumar, Shaji, Simon J. Harrison, Michèle Cavo, et al.. (2020). Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 38(15_suppl). 8509–8509. 23 indexed citations
3.
Piha‐Paul, Sarina A., Jasgit C. Sachdev, Minal Barve, et al.. (2019). First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. Clinical Cancer Research. 25(21). 6309–6319. 116 indexed citations
4.
Moreau, Philippe, Simon J. Harrison, Michèle Cavo, et al.. (2019). Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 1888–1888. 28 indexed citations
5.
Kumar, Shaji, Simon J. Harrison, Michèle Cavo, et al.. (2019). A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(10). e31–e31. 27 indexed citations
6.
Borthakur, Gautam, Johannes Wolff, Ibrahim Aldoss, et al.. (2018). First-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (RR) acute myeloid leukemia (AML): Preliminary data.. Journal of Clinical Oncology. 36(15_suppl). 7019–7019. 12 indexed citations
7.
Borthakur, Gautam, Johannes Wolff, Ibrahim Aldoss, et al.. (2018). First-In-Human Study of ABBV-075 (Mivebresib), A Pan-Inhibitor of Bromodomain and Extra Terminal (BET) Proteins, in Patients (Pts) With Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML): Preliminary Data. Clinical Lymphoma Myeloma & Leukemia. 18. S203–S203. 3 indexed citations
8.
O’Neil, Bert H., Dimple Modi, Patricia LoRusso, et al.. (2018). Gene expression and cytokine modulation in a first in human (FIH) study of a pan BET inhibitor ABBV-075 in solid tumors.. Journal of Clinical Oncology. 36(15_suppl). 2570–2570. 1 indexed citations
9.
Piha‐Paul, Sarina A., Jasgit C. Sachdev, Minal Barve, et al.. (2018). Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (R/R) solid tumors.. Journal of Clinical Oncology. 36(15_suppl). 2510–2510. 8 indexed citations
10.
Falchook, G. S., Siqing Fu, Aung Naing, et al.. (2010). Phase I trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced malignancies.. Journal of Clinical Oncology. 28(15_suppl). 2595–2595. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Connie Qi Breakdown of academic impact, for papers by Ammar Al-Zoubi Breakdown of academic impact, for papers by Edmund C. Lee Breakdown of academic impact, for papers by Noa Biran Breakdown of academic impact, for papers by Edvan de Queiroz Crusoé Breakdown of academic impact, for papers by Claire Torre Breakdown of academic impact, for papers by Joe Bolen Breakdown of academic impact, for papers by Ellen Ingalla Breakdown of academic impact, for papers by Vladimir Vorobyev Breakdown of academic impact, for papers by Evžen Gregora
Rankless by CCL
2026